unspecified valid from 2014-06-10
Revised: 8 April 2014
Accepted: 30 April 2014
First Online: 10 June 2014
: Carlino MS received honoraria from Novartis, Roche, GlaxoSmithKline and Bristol-Myers Squibb. Menzies AM received travel support from Roche and GlaxoSmithKline, and honoraria from Roche. Hamilton AL received travel support from Roche. Cooper WA received consultancies and honararia from Pfizer and Merck. O’Toole S received honoraria from Roche, Astra Zeneca and Pfizer. Thompson JF received consultancies and honoraria from Roche and GlaxoSmithKline. Kefford RF received consultancies and honoraria from Roche, GlaxoSmithKline and Novartis. Scolyer RA received consultancies from Roche and GlaxoSmithKline, honoraria from Abbott Molecular. Long GV received consultancies from Roche, Bristol-Myers Squibb, GlaxoSmithKline, Novartis and Amgen; honoraria from Roche; travel support from GlaxoSmithKline and Roche Melanoma Institute Australia received research support from Roche. The remaining authors declare no conflict of interest.